Germline mutations in the breast cancer susceptibility genes BRCA1 and BRCA2 have been linked to the development of breast cancer, ovarian cancer, and other malignancies. Recent studies suggest that the BRCA1 and BRCA2 gene products may function in the sensing and/or repair of DNA damage. To investigate this possibility, we determined the eects of various DNAdamaging agents and other cytotoxic agents on the mRNA levels of BRCA1 and BRCA2 in the MCF-7 and other human breast cancer cell lines. We found that several agents, including adriamycin (a DNA intercalator and inhibitor of topoisomerase II), camptothecin (a topoisomerase I inhibitor), and ultraviolet radiation induced signi®cant decreases in BRCA1 and BRCA2 mRNA levels. Decreased levels of BRCA1 and BRCA2 mRNAs were observed within 6 ± 12 h after treatment with adriamycin and persisted for at least 72 h. Adriamycin also induced decreases in BRCA1 protein levels; but these decreases required several days. U.V. radiation induced dose-dependent down-regulation of BRCA1 and BRCA2 mRNAs, with signi®cant decreases in both mRNAs at doses as low as 2.5 J/m 2 , a dose that yielded very little cytotoxicity. Adriamycin-induced down-regulation of BRCA1 and BRCA2 mRNAs was ®rst observed at doses that yielded relatively little cytotoxicity and little or no apoptotic DNA fragmentation. Adriamycin and U.V. radiation induced distinct dose-and time-dependent alterations in the cell cycle distribution; but these alterations did not correlate well with corresponding changes in BRCA1 and BRCA2 mRNA levels. However, the adriamycin-induced reduction in BRCA1 and BRCA2 mRNA levels was correlated with p53 functional status. MCF-7 cells transfected with a dominant negative mutant p53 (143 val?ala) required at least tenfold higher doses of adriamycin to downregulate BRCA1 and BRCA2 mRNAs than did parental MCF-7 cells or control-transfected MCF-7 clones. These results suggest that BRCA1 and BRCA2 may play roles in the cellular response to DNA-damaging agents and that there may be a p53-sensitive component to the regulation of BRCA1 and BRCA2 mRNA expression.
Introduction
Germline mutations in the BRCA1 and BRCA2 genes have been linked to an increased risk of development of breast cancer, ovarian cancer, and other malignancies (Miki et al., 1994; Tavtigian et al., 1996) . Mutations in one or the other of these genes are found in approximately 80% of cases of familial breast cancer (Easton et al., 1993) . BRCA1 is an 1863 amino acid phosphoprotein whose levels and phosphorylation state vary during the cell cycle (Gudas et al., 1996; Rajan et al., 1996; Vaughn et al., 1996) . Most evidence suggests that BRCA1 is localized in the nucleus Thomas et al., 1996; Scully et al., 1996) , although cytoplasmic and extracellular distribution has been reported . BRCA1 is thought to be a tumor suppressor gene, since mRNA levels are greatly reduced in invasive breast cancer and since overexpression of BRCA1 inhibits breast cancer cell proliferation in vitro and in an experimental tumor model . Selective reduction of BRCA1 mRNA levels using antisense RNA induces more rapid cell growth, decreased susceptibility to apoptosis, and cell transformation in NIH3T3 fibroblasts (Thompson et al., 1995; Rao et al., 1996) . On the other hand, overexpression of a full-length cDNA construct causes susceptibility to apoptosis in transfected cell lines .
A fusion protein containing the C-terminal region of BRCA1 can activate transcription when linked to a suitable DNA binding domain, suggesting that BRCA1 may function as a transcription factor (Chapman and Verma, 1996; Monteiro et al., 1996) . BRCA1 also contains domains homologous to a recently cloned p53 binding protein (53BP1) and to Rad9, a yeast protein that may regulate the G2 DNA-damage checkpoint (Koonin et al., 1996) . In addition, BRCA1 has been found to associate with Rad51, the human homolog of the bacterial recombinase RecA (Scully et al., 1997b) . The human BRCA2 gene encodes a 3418 amino acid protein that lacks signi®cant sequence homology to known proteins (Tavtigian et al., 1996) . BRCA2 also associates with the Rad51 protein, and BRCA27/7 cells appear to be hypersensitive to ionizing radiation (Sharan et al., 1997) . BRCA1 and BRCA2 mRNA levels are regulated co-ordinately during cell cycle progression and growth arrest (Spillman and Bowcock, 1996; Rajan et al., 1996) , with peak mRNA levels observed at the G1/S interface and low levels in late Sphase (Vaughn et al., 1996; Gudas et al., 1996; Rajan et al., 1996) . Levels of both mRNAs are reduced when mammary epithelial cells become growth-arrested due to serum deprivation (Gudas et al., 1996; Vaughn et al., 1996; Rajan et al., 1996) . These observations suggest that BRCA1 and BRCA2 may function in monitoring genomic integrity and in DNA repair. However, their precise functions remain to be determined.
Based on these considerations, we have investigated the possibility that BRCA1 and BRCA2 might function in the response of cells to DNA-damaging agents and other cytotoxic agents. In this report, we describe the eects of these agents on BRCA1 and BRCA2 mRNA levels in human breast cancer cells, and the eect of the p53 functional status on the response of these cells to the DNA topoisomerase II inhibitor adriamycin (doxorubicin hydrochloride).
Results

Eect of adriamycin (ADR) on BRCA1 and BRCA2 expression in MCF-7 cells with wild-type (WT) or mutant p53
Since BRCA1 has been implicated in the process of apoptosis and since both BRCA1 and BRCA2 may be involved in DNA repair, we examined the expression of BRCA1 and BRCA2 mRNA following treatment of MCF-7 human breast cancer cells with ADR. Cells were treated with 5 mM ADR for 1 h, and mRNA levels were examined 24 h later using semi-quantitative RT ± PCR analysis (see Materials and methods) . Although the cells showed no obvious evidence of cytotoxicity under these conditions (see below), both BRCA1 and BRCA2 mRNA levels were found to be decreased relative to untreated control cells ( Figure  1a) .
MCF-7 cells normally express WT p53 (Wosikowski et al., 1995) . To determine if the ability to downregulate BRCA1 and BRCA2 was p53 dependent, we compared MCF-7 cell clones transfected with a dominant negative mutant p53 (p53 ± 143 val ? ala) (Kern et al., 1992) with parental cells and with control clones transfected with vector containing only the neomycin resistance gene. At a dose of 5 mM ADR, parental cells and three neo-transfected clones showed down-regulation of BRCA1 and BRCA2 mRNA levels 24 h after treatment (Figure 1b) . However, four clones transfected with mutant p53 showed little or no downregulation of BRCA1 or BRCA2 mRNA under the same conditions. Expression of WT vs mutant p53 was con®rmed by Western blotting, as shown in Figure 1c . With the exception of mutant clone 2, mutant transfectants exhibited much higher basal levels of p53 than did parental or control-transfected cells. Treatment of cells containing WT p53 with 5 mM ADR induced an obvious increase in the p53 protein levels, whereas only small increases in p53 protein levels were observed after treatment of cells containing mutant p53. These small changes in p53 levels in the mutant clones may have been due to endogenous WT p53 or to posttranslational modi®cations of the p53 protein. Mutant clone 2 was originally isolated as a transfectant that overexpressed mutant p53 protein. However, Western blotting revealed little or no basal or ADR-induced p53 protein expression, suggesting that this clone may have lost the expression of both wild-type and mutant p53 genes. Mutant clone 2 was therefore functionally negative for p53 protein.
Dose response and time course of ADR-induced decreases in BRCA1 and BRCA2 mRNA levels Dose response To determine if the dierence between WT and mutant MCF-7 cells in the sensitivity of BRCA1 and BRCA2 mRNA levels to ADR was quantitative rather than qualitative, we compared the dose-response relationship for down-regulation of BRCA1 and BRCA2 in parental MCF-7 cells and one of the mutant clones (mutant clone 3). Each cell line showed dose-dependent down-regulation of BRCA1 and BRCA2 expression (Figure 2a ). Downregulation of BRCA1 and BRCA2 in the parental cells was detected at doses of ADR as low as 1 mM, whereas in MCF-7/p53-143 cells, down-regulation required doses of 510 mM ADR. For the parental cell line, the ADR-induced decreases in BRCA1 and BRCA2 mRNA levels appeared to correlate with the ADRinduced increases in WT p53 protein levels ( Figure 2b ). We also observed ADR-induced down-regulation of BRCA1 and BRCA2 in four other human breast cancer cell lines (MDA-MB-231, MDA-MB-453, MDA-MD-468, and T47-D) (data not shown).
Time course Parental MCF-7 cells, sham-treated or treated with ADR (5 mM61 h), were harvested at dierent times after ADR treatment for assessment of BRCA1 and BRCA2 mRNA levels. For each time point, levels of mRNAs were compared in control vs ADR-treated cells. Decreased levels of mRNA for BRCA1 were ®rst detected as early as 6 h after ADR treatment, but these alterations were much more prominent after 12 h (Figure 3a) . Dierences in BRCA1 levels between control and ADR-treated cells persisted for at least 72 h. BRCA2 mRNA levels showed a similar time dependence, with a prominent decrease in BRCA2 observed by 6 h after ADR treatment. Thus, for MCF-7 cells containing WT p53, signi®cant down-regulation of BRCA1 and BRCA2 was observed by 6 ± 12 h after ADR treatment and persisted for at least 3 days.
Protein expression We utilized Western blotting to determine if the down-regulation of BRCA1 mRNA was also associated with decreased expression of the BRCA1 protein. In multiple experiments, by 24 h after treatment of MCF-7 parental cells with 5 mM ADR, there was little or no change in the level of BRCA1 protein. However, at later times (48, 72 and 96 h), BRCA1 protein levels were decreased, as compared with sham-treated control cell harvested at the same times (Figure 3b ). On the other hand, for MCF-7/p53-143 (mutant clone 3) cells, at a dose of 5 mM ADR, there were little or no changes in BRCAl protein levels for the ®rst 72 h; while protein levels at 96 h were lower in ADR-treated cells than in control cells ( Figure  3b ). These ®ndings are consistent with the decreased sensitivity of MCF-7/p53-143 cells to ADR-induced down-regulation of BRCAl mRNA. They also suggest that the BRCAl protein has a longer half-life than the mRNA.
Eect of ADR on survival, apoptosis, and proliferation of MCF-7 cells
We performed several dierent types of studies to determine if the down-regulation of BRCA1 and BRCA2 induced by adriamycin might be directly related to its cytotoxicity. In one set of studies, the dose-dependence of ADR-induced cytotoxicity was assessed 24 h after treatment using the trypan blue dye exclusion assay. In these experiments, we found that the degree of cytoxicity was only slightly greater in MCF-7 parental cells than in MCF-7/p53-143 (mutant clone 3) cells (see Figure 4a) . Thus, the IC 50 s for loss of cell viability were about 17 mM for the parental cells and 22 mM for the p53 mutant cells. For parental cells, the cell`survival' at the dose at which ADR-induced down-regulation of BRCA1/2 was ®rst observed (1 mM) was 96%; and at 5 mM ADR, the survival of these cells was still about 91%. For p53 mutant cells, cell survival at 10 ± 15 mM ADR (the dose at which BRCA1/2 down-regulation was ®rst observed) was also quite high (80 ± 90%). Cell survival was also assayed using the MTT dye conversion assay. Dye conversion activity was assessed 3 days after exposure to ADR, so that these assays are a longer term measure of cytotoxicity. By this assay, the IC 50 values for loss of cell survival were about 13 mM and 17 mM, respectively, for parental and p53 mutant cells. Thus, marked down-regulation of BRCA1 and BRCA2 could be observed at ADR doses that yielded relatively little cytotoxicity.
We compared the growth of MCF-7 parental cells treated without or with ADR (5 mM61 h). These studies revealed no net cell loss in ADR-treated populations of cells, although there was a delay in cell growth between 24 and 48 h (Figure 5a ). The ADR-treated cells continued to grow between 48 and 72 h, even though BRCA1 and BRCA2 mRNA levels remained low at these times (see Figure 3a) . For p53 mutant MCF-7 cells, at a dose of 5 mM ADR, there was no obvious morphological evidence of cytotoxicity; and growth curves revealed an even smaller or no eect on cell growth kinetics. These ®ndings are consistent with the trypan blue assays, demonstrating little or no cytotoxicity at a dose of 5 mM ADR for either cell line.
We also assessed DNA fragmentation in ADRtreated cells as a measure of the entry of cells into apoptosis. There appeared to be little or no induction of apoptosis in MCF-7 cells 24 h after treatment with ADR doses as high as 25 mM, as indicated by the absence of interoligonucleosomal-sized DNA fragments ( Figure 5b ). In contrast, an ADR-sensitive breast cancer cell line (MDA-MB-453) showed marked DNA fragmentation 24 h after treatment with a dose of 5 mM ADR. Taken together, these observations suggest that the down-regulation of BRCA1 and BRCA2 was not a direct consequence of cytotoxicity or cell death.
Eect of ADR on cell cycle progression of MCF-7 cells
BRCA1 and BRCA2 mRNA levels have been found to vary in a cell-cycle dependent fashion (see Introduction). We utilized¯ow cytometric analysis of propidium iodide-stained nuclei to assess the eects of ADR on the cell cycle distributions of initially asynchronous proliferating populations of MCF-7 cells Table 1a ). These alterations were qualitatively similar in parent vs mutant cell lines, but diered at the low vs high ADR doses. Thus, at 1 and 5 mM ADR, the proportion of cells in S-phase decreased, while that in G2/M tended to increase. On the other hand, treatment with 10 and 25 mM ADR showed cells accumulating in late S or throughout S-phase. In time course studies, cells were treated without (7) or with (+) a dose of 5 mM ADR. These assays revealed a time-dependent loss of cells from S-phase and accumulation of cells in G2/M for both parental and p53 mutant cell lines ( Figure 6b , Table 1b ).
These studies suggest that at lower doses (1 ± 5 mM?), the predominant eect of ADR may be to induce partial G1 and G2/M arrest; while cells in S-phase can progress into the G2/M compartment. Thus, the net eect is time-dependent loss of cells from S and accumulation in G2/M. At the higher doses (10 and 25 mM), cells also appear to partially or fully arrest in S, consistent with ADR-mediated inhibition of topoisomerase II and DNA synthesis (Stevensner et al., 1993) . These findings do not appear to be consistent with the idea that ADRinduced changes in BRCA1 and BRCA2 mRNA levels are solely due to cell cycle alterations. For example, after treatment with 5 mM ADR, parental cells showed marked time-dependent loss of BRCA1 and BRCA2 mRNA expression; while similar changes were not observed changes in p53-143 cells. In contrast, the alterations in cell cycle distributions were qualitatively similar in both cell lines. Furthermore, at the 24 h time point, doses of 1, 5, 10 and 25 mM ADR each induced down-regulation of BRCA1 and BRCA2 mRNAs in parental MCF-7 cells; whereas these doses caused distinct changes in cell cycle distribution, characterized by loss of cells from S at lower doses and inhibition of S-phase progression at higher doses.
In both cell lines, there were few or no cells with a sub-G1 DNA content, consistent with the lack of DNA fragmentation on DNA agarose gel electrophoresis. These comparisons suggest that the eects of ADR on BRCA1 and BRCA2 levels do not exactly correspond with ADR-induced changes in the cell cycle distributions of MCF-7 parental or MCF-7/p53-143 cells.
Eects of other cytotoxic agents on BRCA1 and BRCA2 mRNA levels and on cell survival
We studied the eects of a panel of dierent cytotoxic agents on BRCA1 and BRCA2 mRNA levels in parental MCF-7 cells as well as a cell clone expressing mutant p53 (MCF-7/p53-143 mutant clone 3). For this study, we used a relatively high dose of each drug [15 mM61 h, except for paclitaxel (TAXOL) and vincristine (VCR), which were applied for a full 24 h]. Of the agents tested, ADR, camptothecin (CPT), and ultraviolet radiation (U.V.@254 nm, 10 J/m 2 ) induced decreases in BRCA1 and BRCA2 mRNA levels in both parental and MCF-7/p53-143 cells (Figure 7a ). In addition, the microtubuledisrupting agents TAX and VCR and the alkylating agent nitrogen mustard (HN2) also induced detectable decreases in BRCA1 and BRCA2 mRNA levels in MCF-7 parental cells, but not in MCF-7/p53-143 cells.
To determine if the down-regulation of BRCA1 and BRCA2 by cytotoxic agents was related to the ability of these agents to induce increased levels of p53 protein, we performed Western blot analysis under the same conditions. In parental cells, ADR, CPT, and U.V. each induced large increases in the levels of p53 protein, while HN2 induced a smaller increase, and TAX and VCR induced small but detectable increases. In contrast, MCF-7/p53-143 cells expressed relatively high basal levels of p53, which were slightly increased by some of the treatments, particularly CPT. Downregulation of BRCAl and BRCA2 therefore appeared to correlate with the ability of the agents tested to induce large increases in the levels of WT p53 protein in parental MCF-7 cells.
We also determined the eects of the cytotoxic agents on the levels of p21
protein, a p53-regulated inhibitor of G1 cyclin-dependent kinases. Levels of p21 increase in response to induction of p53 by DNA-damaging agents such as ionizing radiation; and p21 mediates the p53-dependent G1 cell-cycle arrest (reviewed by Levine, 1997) . However, for both parental and MCF-7/p53-143 cells, U.V. and ADR each induced decreases in p21 protein levels after 24 h after treatment, while CPT induced an increase in p21 levels (Figure 8 ). Thus, p21
waf/cip1 protein levels and BRCA1 and BRCA2 mRNA levels do not appear to be co-ordinately regulated in MCF-7 cells. Figure 7b shows the eects of the same cytotoxic treatments on cell survival, using the trypan blue dye exclusion assay. For both parental and p53 mutant cell lines, each of the agents tested caused some degree of cytotoxicity. However, the ability of an agent to downregulate BRCA1 and BRCA2 mRNAs did not appear to be directly linked to cytotoxicity. For example, at a cell survival level of about 80%, HN2 (Figure 7b ) and ADR (Figure 4a ) induced marked down-regulation. On the other hand, the microtubule disrupting agents TAX and VCR induced marked toxicity in both parental and p53 mutant cells (ca. 50% survival); but these agents induced down-regulation of BRCA1 and BRCA2 only in the parental cells. The agents CDDP, VP-16, and dFdC were toxic to parental and mutant cells (cell survival levels from about 55 ± 90%), but did not cause down-regulation of BRCA1 or BRCA2 in either cell line. While a U.V. dose of 10 J/m 2 potently down-regulated BRCA1 and BRCA2 expression, this dose was markedly cytotoxic for parental MCF-7 cells (30% survival after 24 h). We, therefore, performed additional studies to determine if down-regulation occurred at lower U.V. doses. U.V. treatment induced dosedependent down-regulation of BRCA1 and BRCA2 mRNAs (Figure 9a ). Decreased levels of both mRNAs were observed at the lowest dose tested (2.5 J/m 2 ); and a dose of 5 J/m 2 was sucient to induce maximal down-regulation. At these U.V. doses, cell survival levels measured by trypan blue dye exclusion were about 90% and 75%, respectively (Figure 9b ). Survival levels declined progressively with increasing dose, with less than 10% surviving cells at a dose of 20 J/m 2 . These ®ndings are qualitatively similar to the results obtained with ADR; and they suggest that higher doses of U.V. radiation are required to reduce cell viability than are required to inhibit BRCA1 and BRCA2 mRNA expression.
The eect of U.V. treatment on the cell cycle distribution of parental MCF-7 cells is shown in Figure 9c and in Table 2 . At 24 h after irradiation, U.V. induced an increase in the G0/Gl population (up to +12%), associated with small-moderate decreases in the proportion of cells in the S and G2/M phases [up to 7(5 ± 8)%]. These ®ndings are consistent with a U.V.-induced G1 cell cycle arrest. In contrast, in the same cell line, ADR induced predominantly a G2 cell cycle arrest (Figure 6 ). Furthermore, a U.V. dose of 2.5 J/m 2 , which was sucient to cause marked down-regulation of BRCA1 and BRCA2 mRNAs, had relatively little eect on cell cycle distribution at 24 h, at which time there was no net loss of cells from S-phase. Thus, while ADR and U.V. radiation each induced dosedependent down-regulation of BRCA1 and BRCA2 mRNA expression, the eects of these two DNAdamaging agents on the cell cycle distribution of MCF-7 cells were distinct.
Discussion
We show here that in MCF-7 human breast cancer cells, levels of mRNAs for the breast cancer susceptibility genes BRCA1 and BRCA2 were reduced following treatment with cytotoxic agents that are potent inducers of the wild-type p53 tumor suppressor protein. These agents include adriamycin, camptothecin, and ultraviolet radiation. For ADR, decreased levels of BRCAl and BRCA2 were ®rst observed between 6 and 12 h after drug treatment and were dose-dependent. The ADR-induced down-regulation of BRCA1 and BRCA2 did not appear to be directly related to the induction of apoptotic DNA fragmenta- Cells were treated and analysed as described in the Materials and methods section. These data correspond to the¯ow cytometry histograms shown in Figure 6a and Figure 6b , respectively tion or cell death. Thus, in wild-type MCF-7 cells, prominent down-regulation of BRCA1 and BRCA2 mRNAs was observed at ADR or U.V. doses for which cell survival was 590%. It is unlikely that the down-regulation of BRCA1 and BRCA2 in wild-type MCF-7 cells was solely due to alterations of the cell Figure 7 Eect of dierent cytotoxic agents on BRCA1/BRCA2 mRNA levels and cell viability in MCF-7 parental and MCF-7/ p53-143 cells. Cells were treated with dierent agents; and 24 h after treatment, total cell RNA was extracted for semi-quantitative RT ± PCR analysis of BRCA1, BRCA2, and b-actin (a). In a parallel experiment, cultures were harvested 24 h after treatment for assessment of cell viability using the trypan blue dye exclusion assay (b Figure 8 Eect of dierent cytotoxic agents on the p53 and p21 protein levels in MCF-7 parental and MCF-7/p53-143 cells. Cells were treated with cytotoxic agents as described in Figure 7 legend and in the text. After 24 h, p53 and p21 levels were determined by Western blotting cycle distribution, since (1) the dose-and timedependent alterations in cell cycle distribution induced by ADR and U.V. did not correlate well with alterations in BRCA1 and BRCA2 mRNA levels; and (2) U.V. radiation and adriamycin ± both of which potently down-regulated BRCA1 and BRCA2 ± caused qualitatively distinct cell cycle alterations. Thus, our ®ndings suggest that human breast cancer cells respond to certain types of DNA damage by down-regulating BRCA1 and BRCA2 expression. While the BRCAl and BRCA2 mRNA responses occurred by 6 ± 12 h after ADR treatment, downregulation of the BRCA1 protein required longer times (424 h), presumably because the protein has a longer half-life than the mRNA. The lack of immediate quantitative down-regulation of BRCA1 protein does not neccessarily mean that BRCA1 is not involved in very early cellular responses to DNA damage. One recent study indicates that DNA damage of MCF-7 cells (by U.V., gamma rays, or mitomycin C) caused a very rapid (51 h) redistribution of BRCA1 and several BRCA1 binding partners (Rad51 and BARD1) to multi-protein complexes containing proliferating cell nuclear antigen (PCNA) and damaged DNA (Scully et al., 1997a) . In parallel with nuclear redistribution in Sphase, hyper-phosphorylation of BRCA1 was observed. The authors speculated that BRCAl localizes at sites of replication-related DNA repair, and that BRCA1 may participate in an S-phase DNA-damage check-point response. Interestingly, BRCA1-mediated cell cycle arrest was found to require the p21wa¯/cipl protein; and BRCA1 was found to transactivate p21 promoterreporter constructs even in the absence of the p53 binding sites . In another study utilizing normal mammary epithelial cells, consitutive expression of a BRCA1 cDNA contstruct encoding only the C-terminal transcription activation domain led to more rapid cell cycle progression and failure of nocodazole, a mitotic spindle poison, to arrest cells in M (Larson et al., 1997) . Thus, BRCA1 may also be involved in a G2-M cell cycle check-point mechanism.
In the context of these considerations, we speculate that the delayed loss of BRCA1 in ADR and U.V.-treated cell lines may be part of a survival response that allows cells that have suciently repaired their DNA damage to re-enter the cell cycle or that protects these cells against BRCA1-mediated apoptosis. This idea is consistent with the observations that overexpression of BRCA1 causes inhibition of cell proliferation and renders cells more susceptible to the induction of apoptosis ; whereas, antisense inhibition of BRCA1 expression stimulates cell proliferation and renders 53 30 17 a Cells were treated with U.V.-C. radiation at room temperature, incubated at 378C for 24 h, and then analysed as described in the Materials and methods section. These data correspond to the¯ow cytometry histograms shown in Figure 9c cells more resistant to the induction of apoptosis (Thompson et al., 1995; Rao et al., 1996) . It has been reported that breast cancers from patients with germline mutations of BRCA1 or BRCA2 have a 2 ± 3-fold increase of chromosomal loss as compared to sporadic cancers (Tirkkonen et al., 1997) . This ®nding is also consistent with the idea that the loss of BRCA1 may permit the survival and subsequent proliferation of cells with residual DNA damage. Taken together with the recent reports that the BRCA1 and BRCA2 proteins can associate with the DNA recombinase/repair protein Rad51, these observations suggest possible roles for BRCA1 and BRCA2 in the sensing of and/or response to some forms of DNA damage.
The p53 dependence of ADR-induced BRCA1 and BRCA2 response suggests that p53 may collaborate with BRCA1 and BRCA2 in the detection of and response to DNA damage. The mechanism of this presumed collaboration is unclear. One possibility is that p53 induces transcriptional silencing of the BRCA1 and BRCA2 genes, a possible mechanism for the p53-induced down-regulation of the Bcl-2 cell survival gene (Miyashita et al., 1994) . However, there are other possible mechanisms for the ADR-induced decreases in BRCA1 and BRCA2 levels, including post-transcriptional alterations leading to a decreased half-life of the BRCA1 and BRCA2 mRNAs. Recently, p53 has been found to bind to several dierent proteins, including components of the TFIIH RNA polymerase II basal transcription factor (helicases ERCC2 and ERCC3), other transcription factors (TATA box-binding protein, TAF70, TAF30), the protein kinase c-Abl, and two novel p53-binding proteins designated 53BP1 and 53BP2 Bork et al., 1997; Datta et al., 1996; Naumovski and Cleary, 1996; Gorina and Pavletich, 1996; Callebaut and Mornon, 1997) . 53BP1 and 53BP2 bind to the region of the p53 sequence-speci®c DNAbinding domain (between residues 102 and 292), but the precise binding sites for DNA binding and binding to these two proteins may not be identical (Thukral et al., 1996) .
Interestingly, protein sequence analysis suggests the presence of domains homologous to 53BP1 in the Cterminal region of BRCA1 and in other proteins thought to be involved in DNA-damage cell cycle checkpoints and/or in DNA repair (Koonin et al., 1996) . The 53BP1-like domain in the C-terminus of BRCA1 corresponds closely to the recently identi®ed minimal transactivational domain of BRCA1 (Chapman and Verma, 1996; Monteiro et al., 1996) . An interferon-inducible transcriptional inhibitor (p202 in the mouse) binds to the murine homolog of 53BP1 and inhibits the expression of reporter genes under the control of several p53-activatable promoter segments (p21 waf/cip1 and Mdm2) (Datta et al., 1996) . 53BP2 can directly bind to and inhibit the activity of protein phosphatase 1 (PP1), suggesting that it might be involved in dephosphorylation and regulation of p53 (Helps et al., 1995) . These considerations raise the possibility that selective competing interactions among members of this group of proteins (p53, 53BP1, 53BP2, BRCA1, PP1, and p202-like proteins) may mediate dierent aspects of the cellular response to DNA damage. Particularly intriguing are the possibilities that p53 may either directly bind to the Cterminal 53BP1-like domain of BRCA1 or that 53BP1 may compete with this domain for binding to other factors (e.g. p202-like proteins) and thereby regulate p53-mediated transcriptional activation of target genes.
Although p53 may play a role in modulating the ability of breast cancer cells to down-regulate BRCA1 and BRCA2 expression, it is clear from our studies that various cytotoxic agents can induce downregulation in breast cancer cell lines that contain mutant p53. It is interesting that two agents that potently down-regulate BRCA1 and BRCA2 mRNA expression (ADR and U.V.) also paradoxically induced down-regulation of p21 protein levels. This downregulation was observed in MCF-7 cells containing wild-type or mutant p53; and in wild-type MCF-7 cells, down-regulation of p21 expression occurred in spite of the activation of p53. The mechanism(s) of p53-independent regulation of p21 expression have not been elucidated; but several recent reports have implicated p300 and BRCA1 as potential transcriptional activators of p21. Thus, p53-mediated transcriptional activation of a p21 promoter-reporter construct was blocked by a speci®c interaction of adenovirus E1A with the transcriptional adapter molecule p300 ; and transfection of BRCA1 into human carcinoma cells activated the p53-independent transcription of a p21 promoterreporter construct .
It is unlikely that the down-regulation of p21 is related found in our study is causally linked to the down-regulation of BRCA1, since BRCA1 protein levels do not decline until after 24 h. However, it is possible that p300 or its homolog p265/CBP may be involved in the p53-independent regulation of p21 in ADR and U.V. treated breast cancer cells. It is not known if p300 or p300-related proteins play a signi®cant role in the cellular response to DNAdamaging agents.
In conclusion, we found that several DNA-damaging agents induced down-regulation of BRCA1 and BRCA2 mRNA levels in MCF-7 and other human breast cancer cell lines. The sensitivity of MCF-7 cells to adriamycin-induced down-regulation of BRCA1 and BRCA2 was correlated with the p53 functional status of the cells. These ®ndings are consistent with the hypothesis that BRCA1 and BRCA2 participate in the detection and/or repair of DNA damage. Further research is required to establish the mechanism(s) and functional signi®cance of down-regulation of BRCA1 and BRCA2.
Materials and methods
Materials
All cell lines studied were initially obtained from the American Type Culture Collection. Cell culture reagents were purchased from BioWhittaker. TriPure TM , G418, and PCR reagents were obtained from Boehringer Mannheim. Lipofectamine TM , reverse transcriptase, and PCR primers were products of Life Technologies. The p53 and control plasmids were generous gifts of Dr Bert Vogelstein. Other reagents were obtained from Sigma Biochemical Corp.
The primary antibodies used for Western blotting were as follows: p53 [Ab-2 (pAb1801), mouse monoclonal, Oncogene Research Products]; BRCA1 (C-20, rabbit polyclonal IgG, Santa Cruz Biotechnology); p21 (H-164 mouse monoclonal, Santa Cruz); and a-actin (I-19, rabbit polyclonal IgG, Santa Cruz). The BRCA1 antibody was raised against a peptide corresponding to amino acids 1843 ± 1862 mapping to the Cterminus of human BRCA1. Horseradish peroxidase-conjugated secondary antibodies were purchased from Santa Cruz.
Cell culture
Cell lines were maintained in DMEM supplemented with 10% fetal calf serum (v/v), L-glutamine (5 mM), nonessential amino acids (5 mM), penicillin (100 U/ml), and streptomycin (100 mg/ml), as previously described (Rosen et al., 1991) .
Generation of p53 transfectants
Transfections were performed using Lipopectamine TM Reagent (Life Technologies) according to the manufacturer's instructions. MCF-7 cells, which contain wild-type p53, were transfected with plasmid pC53-SCX3, which contains a cDNA encoding a dominant negative mutant p53 (p53-143 val ? ala) and the neomycin resistance gene (Kern et al., 1992) . Control cells were transfected with the parent vector pCMV-neo-bam. Transfectants were selected in 0.5 mg/ml G418 and isolated using cloning rings. Transfected clones were screened for p53 functional status by Western blotting of p53 in cells treated without and with adriamycin (see Results) and U.V. radiation (data not shown). Cell clones that stably expressed mutant p53 or neo only were frozen and stored in liquid nitrogen.
Treatment with cytotoxic drugs and U.V. radiation Cells were grown in 100 mm plastic Petri dishes to about 40 ± 50% of con¯uence and then exposed to ADR (5 mM61 h) in DMEM supplemented with 5% fetal calf serum. Cells were then washed twice in serum-free medium and incubated at 378C in fresh DMEM containing 5% serum for 24 h. Control cells were treated identically, except that no ADR was added. Cells were then solubilized in TriPure TM for RNA extraction or in protein lysis buer for Western blotting. In some cases, dierent doses of ADR and dierent post-ADR incubation times were tested; and in other experiments, dierent cytotoxic drugs were utilized (as described in the Results and Figure  legends) . U.V. irradiation was performed at 258C using U.V.-C. radiation (254 nm) from a Philips U.V. lamp at a dose rate of 10 J/m 2 min. The dose intensity was measured using a BlackRay W meter (model J-225, UVP Inc.). Culture medium was removed immediately before U.V. treatment; and fresh medium was added back immediately after treatment. Cells were then post-incubated at 378C for 24 h as described above.
Semi-quantitative RT ± PCR analysis
Total cell RNA was extracted from cell monolayers using TriPure TM reagent, according to the manufacturer's instructions. The extracted RNA was treated with DNase and puri®ed by phenol-chloroform extraction. Aliquots of RNA (5 mg) were then reverse transcribed using Superscript II TM reverse transcriptase (Life Technologies). Aliquots of cDNA corresponding to 0.5 mg of original RNA were used for PCR ampli®cation. PCR ampli®cation was performed in a Perkin-Elmer DNA thermal cycler. DNA was ®rst denatured for 3 min at 948C, then ampli®ed using cycles of 1 min at 948C, 1 min at 508C, and 1 min at 728C, with a ®nal 7 min incubation at 728C. The cycle number was adjusted so that all reactions were within the linear range of product ampli®cation. The forward and reverse PCR primers and the expected sizes of the PCR products were as follows:
BRCA1:
5'?3' TTGCGGGAGGAAAATGGGTAGTTA; 3'?5' TGTGCCAAGGGTGAATGATGAAG; 285 bp BRCA2:
5'?3' CGTACACTGCTCAAATCATTC; 3'?5' GACTAACAGGTGGAGGTAAAG; 248 bp b-Actin: 5'?3' TTGTTACCAACTGGGACGATA; 3'?5' GATCTTGATCTTGGTGCT; 764 bp
The 287 bp segment ampli®ed from BRCA1 was located from positions 5239 to 5502 in the published cDNA sequence (GenBank accession number U15595, submitted by Miki et al., 1994) . The 248 bp segment ampli®ed from BRCA2 was located from positions 9833 to 10081 in the published cDNA sequence (GenBank accession number U43746, submitted by Tavtigian et al., 1996) . b-actin was ampli®ed as a control, resulting in a 764 bp product located from positions 265 to 1028. The identity of each of the three PCR products was con®rmed by complete sequencing of the puri®ed product, performed at the DNA sequencing facility at Albert Einstein College of Medicine (Bronx, NY). PCR products were analysed by electrophoresis through agarose gels containing ethidium bromide.
DNA fragmentation assay
Cells to be assayed were detached with trypsin and counted. Samples were normalized to cell number (500 000 ± 750 000 cells) and washed twice in phosphatebuered saline (PBS). Apoptotic DNA was assessed by a minor modi®cation of the protocol described by Hermann et al. (1994) . Cells were lysed in 0.1 ml of DNA lysis buer (1% NP-40, 20 mM EDTA, 50 mM Tris-HCl, pH 8.0) and centrifuged for 5 min at 1600 g. The pellet was re-extracted with 0.1 ml of DNA lysis buer; and the supernatants were combined. SDS was added to a ®nal concentration of 1%; and the lysates were treated with 5 mg/ml of RNase A for 2 h at 568C. Proteinase K was added to a ®nal concentration of 2.5 mg/ml; and the lysates were incubated for 2 h at 378C. DNA was precipitated by the addition of 0.1 ml of ammonium acetate (3 M, pH 5.5) and 0.75 ml of ethanol and incubation for 30 min at 7808C. After microfuging, pellets were re-suspended in Tris-EDTA buer and electrophoresed through 1.2% agarose gels containing 0.1 mg/ml of ethidium bromide.
Western blotting
Cells were centrifuged, washed with phosphate-buered saline (PBS), and lysed at 08C for 30 min in 100 ± 200 ml of lysis buer per 100 mm dish [1% NP-40, in PBS containing 2 mM 4-(2-aminoethyl)-benzen-sulfonyl¯uoride, 10 mg/ml leupeptin, 10 mg/ml aprotinin, 10 mM NaF, 1 mM Na orthovandate, and 5 mM Na pyrophosphate). Protein concentrations were determined using the BioRad dyebinding microassay. Equal aliquots of protein (100 mg/lane) were electrophoresed through 8% or 12% SDS-polyacrylamide gels after boiling for 5 min in Laemmli sample buer. Proteins were then transferred to PVDF membranes and blocked in Tris-Tween blocking buer containing 5% non-fat dry milk. Membranes were then blotted with the appropriate antibody at a dilution of 1 : 1000 (p53, p21, aactin) or 1 : 300 (BRCA1) and then incubated with horseradish peroxidase-conjugated secondary antibody at a dilution of 1 : 3000. Blotted proteins were visualized using the enhanced chemiluminescence detection system (Amersham Life Sciences). Equality of protein loading was con®rmed by fast green staining of the membrane and by immunoblotting for a-actin. Colored markers (BioRad Corp.) were used as molecular size standards.
Growth curves
Cells suspended in DMEM containing 5% fetal calf serum were plated at a density of 40 000 cells in 0.5 ml of medium per well in 24-well plates on Day 2. On Day 0, cells were treated with ADR (5 mM61 h), as described above. At dierent times, cells were detached using trypsin, and the entire contents of each well was counted using a model ZM 901 Coulter Counter TM . Values are expressed as means+s.d. of triplicate determinations.
Cytotoxicity assays
Trypan blue dye exclusion assay Cells to be assayed were harvested using trypsin and stained with 0.4% trypan blue dye. Trypan blue positive and negative cells were counted using a hemacytometer under phase contrast microscopy. At least two ®elds of over 500 cells were assessed for each sample assayed. Cell viability (`survival fraction') was calculated as the percentage of cells that excluded trypan blue dye.
MTT dye conversion assay MTT assays were performed as described before (Alley et al., 1988) . This assay is based on the the ability of viable cells to convert MTT, a soluble tetrazolium salt [3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyl tetrazolium bromide] into an insoluble formazan precipitate, which is quantitated by spectrophotometry following solubilization in dimethyl sulfoxide. Brie¯y, subcon¯uent cells in 96-well dishes were treated with cytotoxic agents and then post-incubated for 3 days in the absence of the agent. At this time, the cells were solubilized and absorbance readings were taken using a Dynatech 96-well spectrophometer. The amount of MTT dye reduction was calculated based on the dierence between absorbance at 570 nm and at 630. Cell`survival' was expressed as the amount of dye reduction relative to that of untreated control cells.
Flow cytometry
Samples were prepared for¯ow cytometry as described by Fan et al. (1995) . Cells were detached using trypsin, washed in PBS, and ®xed in 75% ethanol. Fixed cells were stored at 48C until use. Cells were then washed in PBS, treated with RNase (500 units/ml, Sigma) for 15 min at 378C and stained with propidium iodide (50 mg/ml in PBS). Cell cycle analysis was performed on a BectonDickinson Fluorescence-Activated Cell Sorter at the¯ow cytometry facility of the Albert Einstein College of Medicine (Bronx, NY). The data were analysed to obtain cell cycle distributions using the MODFIT program.
